~~<i id='299B574FC6'><strike id='299B574FC6'><tt id='299B574FC6'><pre id='299B574FC6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：hotspot 2025-10-01 17:56:44 - browse：15

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Sanofi CEO defends move to abandon profit guidance, boost research

hotspot

explore

leisure time

hotspot

entertainment

focus

AdobeGeneralCatalyst’splantotakeoverahospitalinthecomingmonthscouldbethefirstofmanysuchdeals,drivenb

WSS

Judge rejects Trump's request to move Stormy Daniels hush

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

The Sacklers, horror, and ‘The Fall of the House of Usher’

Study: New antibiotic targets gonorrhea as well as last existing drug

hotspot

entertainment

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

State Dept. review finds Biden bears some blame for Afghanistan failures

Ambulance rides for just $100? Advisers want major billing fixes

State Dept. review finds Biden bears some blame for Afghanistan failures

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A clever new way to fix Medicaid and graduate medical education

ChatGPT in medicine: STAT answers readers' burning questions

FDA approves potent Eli Lilly obesity drug, Zepbound

explore

Study identifies new proteins linked to dementia risk 25 years later

Study: New antibiotic targets gonorrhea as well as last existing drug

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Affordable Connectivity Program vital to health care, experts say

I learned firsthand about improving diversity in clinical trials

Removing probiotics from the NICU could threaten preemies' health

leisure time

hotspot

entertainment

focus